Bone marrow stromal dysfunction in mice administered cytosine arabinoside

被引:18
|
作者
Ben-Ishay, Z [1 ]
Barak, V
机构
[1] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Anat & Cell Biol, IL-91010 Jerusalem, Israel
[2] Hadassah Med Ctr, Dept Oncol, Immunol Lab Tumor Diag, IL-91120 Jerusalem, Israel
关键词
bone marrow stroma; cytosine arabinoside (Ara-C); induced damage; contact and non-contact co-culture; CFU-F; HPPC;
D O I
10.1034/j.1600-0609.2001.066004230.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. The aim of the study was to investigate ex-vivo the bone marrow (BM) stroma of mice under conditions of low- and high-dose cytosine arabinoside (Ara-C), a cycle-specific drug (S-phase) and to assess possible stromal damage, apart from the killing of hematopoietic cells. Stroma consists of mesenchymal elements generally not in the cell cycle; therefore, it could not be a target for the killing effect of Ara- C. Materials and Methods. The stromal function was studied by the following: the incidence of stromal stem cells, i.e. CFU-F; formation of stromal layers under growth conditions of long-term culture (LTC) followed by irradiation and overlayering of test cells in contact and noncontact co-cultures; subsequent culture of the test cells in a semi-solid medium to assay the incidence of hyperproliferative potential cells (HPPC); production of GM-CSF, IL-3, IL-4, IL-6 and IFN gamma in the conditioned medium (CM) of confluent stromal layers. All tests and assays were carried out on BM specimens, 1-4 d after Ara-C administration and on controls. Results. Low-dose Ara-C induces a marked decrease of CFU-F, compensated by cycle induction of pre-CFU-F, young-type stromal stem cells. High-dose Ara-C causes a CFU-F decrease to almost zero level. The time length to layer confluency is normal after low-dose Ara-C (similar to 10 d) and prolonged after a high dose (similar to 30 d). The confluent layers from mice receiving low- or high-dose Ara-C support hematopoiesis adequately. Among the growth factors and: cytokines assayed, only IL-6 is detected in CM layers. IL-6 decreases after a low dose of Ara-C and increases after a high dose. The cause of IL-6 fluctuations is yet to be investigated. It is, however, evident that IL-6 is not an essential factor in support of hematopoiesis. Conclusions. Taken together, the current study in mice indicates that Ara-C administration, in particular a high dose, induces bone marrow stromal damage and/or disfunction. The long period of time to roach layer confluency after a high Ara-C dose might reflect the in-vivo situation of slow stromal regeneration.
引用
收藏
页码:230 / 237
页数:8
相关论文
共 50 条
  • [31] The stromal composition of malignant lymphoid aggregates in bone marrow: variations in architecture and phenotype in different B-cell tumours
    Vega, F
    Medeiros, LJ
    Lang, WH
    Mansoor, A
    Bueso-Ramos, C
    Jones, D
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (03) : 569 - 576
  • [32] GAMMA-IRRADIATION RESPONSE OF COCULTIVATED BONE-MARROW STROMAL CELL-LINES OF DIFFERING INTRINSIC RADIOSENSITIVITY
    SANTUCCI, MA
    FITZGERALD, TJ
    HARIGAYA, K
    WODA, B
    SAKAKEENY, MA
    ANKLESARIA, P
    KASE, K
    HOLLAND, CA
    GREENBERGER, JS
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 18 (05): : 1083 - 1092
  • [33] Does osteogenic potential of clonal human bone marrow mesenchymal stem/stromal cells correlate with their vascular supportive ability?
    Merryweather-Clarke, Alison T.
    Cook, David
    Lara, Barbara Joo
    Hua, Peng
    Repapi, Emmanouela
    Ashley, Neil
    Lim, Shiang Y.
    Watt, Suzanne M.
    STEM CELL RESEARCH & THERAPY, 2018, 9
  • [34] Does osteogenic potential of clonal human bone marrow mesenchymal stem/stromal cells correlate with their vascular supportive ability?
    Alison T. Merryweather-Clarke
    David Cook
    Barbara Joo Lara
    Peng Hua
    Emmanouela Repapi
    Neil Ashley
    Shiang Y. Lim
    Suzanne M. Watt
    Stem Cell Research & Therapy, 9
  • [35] Requirement of soluble factors produced by bone marrow stromal cells on the growth of novel established human myeloma cell line
    Aikawa, S
    Hatta, Y
    Tanaka, M
    Kaneita, Y
    Yasukawa, K
    Sawada, U
    Horie, T
    Tsuboi, I
    Aizawa, S
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2003, 22 (03) : 631 - 637
  • [36] Stromal bone marrow fibroblasts and mesenchymal stem cells support acute myeloid leukaemia cells and promote therapy resistance
    Miari, Katerina E. E.
    Williams, Mark T. S.
    BRITISH JOURNAL OF PHARMACOLOGY, 2024, 181 (02) : 216 - 237
  • [37] Impact of stromal cell composition on BMP-induced chondrogenic differentiation of mouse bone marrow derived mesenchymal cells
    Taipaleenmaki, Hanna
    Suomi, Salla
    Hentunen, Teuvo
    Laitala-Leinonen, Tiina
    Saamanen, Anna-Marja
    EXPERIMENTAL CELL RESEARCH, 2008, 314 (13) : 2400 - 2410
  • [38] Human cytidine deaminase as an ex vivo drug selectable marker in gene-modified primary bone marrow stromal cells
    Eliopoulos, N
    Al-Khaldi, A
    Beauséjour, CM
    Momparler, RL
    Momparler, LF
    Galipeau, J
    GENE THERAPY, 2002, 9 (07) : 452 - 462
  • [39] K562 chronic myeloid leukemia cells modify osteogenic differentiation and gene expression of bone marrow stromal cells
    Kumar, Atul
    Anand, Trishna
    Bhattacharyya, Jina
    Sharma, Amit
    Jaganathan, Bithiah Grace
    JOURNAL OF CELL COMMUNICATION AND SIGNALING, 2018, 12 (02) : 441 - 450
  • [40] Human cytidine deaminase as an ex vivo drug selectable marker in gene-modified primary bone marrow stromal cells
    N Eliopoulos
    A Al-Khaldi
    CM Beauséjour
    RL Momparler
    LF Momparler
    J Galipeau
    Gene Therapy, 2002, 9 : 452 - 462